[65] and [66] performed survival analysis using individual EMT hallmark molecules such as E-cadherin and vimentin and showed that none of these molecules could separate LUAD or bladder cancer patients into significantly different prognostic groups. This evidence concerns the gene VIM and urinary bladder cancer.